FOLFOX-HAIC联合仑伐替尼和免疫检查点抑制剂治疗TACE抵抗后肝细胞癌的疗效及安全性分析

FOLFOX-HAIC combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma after the occurrence of TACE refractoriness:analysis of efficacy and safety

二维码有效期 120s

摘要目的评价 FOLFOX(fluorouracil and leucovorin and oxaliplatin)方案肝动脉灌注化疗(hepatic artery infusion chemotherapy,HAIC)联合仑伐替尼(lenvatinib,LEN)和免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在经动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)抵抗后肝细胞癌(hepatocellular carcinoma,HCC)患者中的疗效及安全性.方法回顾分析2019年1月至2022年12月江苏省肿瘤医院54例HCC患者TACE抵抗后接受FOLFOX-HAIC联合LEN和ICIs的临床资料,采用改良实体瘤疗效评价标准(modified response evaluation criteria in solid tumors,mRECIST)统计分析临床疗效,常见不良事件通用术语标准 5.0 版(common terminology criteria for adverse events version 5.0,CTCAE 5.0)记录和评估治疗相关不良事件(treatment related adverse events,TRAEs),主要研究终点为无进展生存期(progression free survival,PFS)和总生存期(overall survival,OS),次要研究终点为客观缓解率(objective response rate,ORR),疾病控制率(disease control rate,DCR)和安全性.结果中位无进展生存期(mPFS)为 11.7 个月(95％CI:8.124～15.276),中位总生存期(mOS)23.1 个月(95％CI:19.508～26.692),ORR 46.3％,DCR 87.0％.各级最常见TRAEs是丙氨酸转氨酶升高(51.9％),最常见3/4级TRAEs是高血压(9.3％),未观察到与治疗相关死亡事件的发生.结论 FOLFOX-HAIC联合LEN和ICIs治疗TACE抵抗后HCC患者安全、有效.